Shutting down air traffic worldwide is no match for the #CharlestonHFpEFConference! Sheldon Litwin getting us started. Standing room only! MUSC Cardiology Fellowship Programs Kavita Sharma Mikhail Kosiborod Harriette Van Spall, MD MPH Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Molly Silkowski, DO James Fang Michele Esposito Michael Felker

Mikhail Kosiborod from Saint Luke's Mid America Heart Institute kicks us off with everything new with SGLT2i and GLP1 agonists and shares a newly proposed treatment algorithm for HFpEF. #CharlestonHFpEFConference Andrew J Sauer MD Brett Sperry, MD Jennifer Hajj, RN Sheldon Litwin Kavita Sharma Dan Silverman

Fascinating new observation from #STEPHFpEF by Sanjiv J. Shah, MD & Mikhail Kosiborod #GLP1RA semaglutide leads to *outsized* reductions in diuretic needs in patients with HFpEF compared with other core medical therapies Article 🔗 academic.oup.com/eurheartj/adva… Editorial 🔗 academic.oup.com/eurheartj/adva…

The story that started with STEP-HFPEF Program continues with SUMMIT topline results announced today. Future is bright for incretin-based therapies to become foundational in HFpEF Andrew J Sauer MD Muthu Vaduganathan Brett Sperry, MD Dr. Deepak L. Bhatt C. Michael Gibson MD investor.lilly.com/news-releases/…

*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside scottdavidsolomon Pardeep S Jhund bayer.com/media/en-us/fi…

We are proud to announce the first patient enrollment today at Saint Luke's Mid America Heart Institute for the fourth and final clinical trial (FINALITY-HF) of the larger MOONRAKER program on finerenone in heart failure. FINEARTS-HF, the first in the finerenone program,

Friday morning session at #ESC2024 Everything you wanted to learn about semaglutide, focused on obesity and heart failure, 😞 inflammation, atrial fibrillation, echo markers, CKD and more! 🔥 we kick off the Congress! European Society of Cardiology Mikhail Kosiborod Muthu Vaduganathan BiykemBozkurt

Exciting Fri at #ESCCongress for JACC Journals and our authors publishing groundbreaking research: 5 LATE BREAKING SCIENCE papers Many semaglutide studies (STEP-HFpEF, FLOW, SELECT) and much more… #CardioTwitter #ESC2024 American College of Cardiology Mikhail Kosiborod Subodh Verma scottdavidsolomon

Proof I made it to European Society of Cardiology Let’s go! Check out JACC Journals publications our team is releasing soon during London sessions. jacc.org/events/confere… Mikhail Kosiborod John Spertus Saint Luke's Mid America Heart Institute Saint Luke's

Semaglutide and obesity related HFpEF Patients with atrial fibrillation and obesity HFpEF are generally more burdened/congested at baseline and also may benefit more from GLP1 in health status and walking distance. Mikhail Kosiborod Saint Luke's Mid America Heart Institute jacc.org/doi/10.1016/j.…

Semaglutide and obesity HFpEF Echo markers Improved LA volume reduction and markers of diastolic function with GLP1 compared to placebo. Muthu Vaduganathan BiykemBozkurt Mikhail Kosiborod

Pooled analysis of patients with HFpEF in STEP-HFpEF, SELECT, and FLOW Mikhail Kosiborod Saint Luke's Mid America Heart Institute Saint Luke's Muthu Vaduganathan

Amazing pooled analysis of outcomes for pts at Select, Flow and STEP-HFPEF trials presented by Mikhail Kosiborod. A highly significant reduction in CV death ir HF events. No significant reduction in CV death when outcomes are analysed separately. #ESCCongress 2024

#JACC was proud to publish 5️⃣ of the 7️⃣ Late Breaking Science papers from STEP-HFpEF, SELECT, & FLOW, evaluating #semaglutide in CV, CKD, & #HeartFailure populations, ➕ effect on #COVID19. Explore our 🆕 #obesity site with commentary from Harlan Krumholz et al. on the Obesity

1/🧵 Subodh Verma Mikhail Kosiborod and colleagues have published important findings JACC Journals on inflammation in obesity-related HFpEF from the STEP-HFpEF Program. Let's break it down! #CardioTwitter #HFpEF #ESCCongress jacc.org/doi/10.1016/j.…

JACC Journals Novo Nordisk 11/11 This study represents a significant step forward in our understanding of obesity-related HFpEF and potential treatment strategies. Kudos to Subodh Verma Mikhail Kosiborod and the entire research team! #ESCCongress JACC Journals

JACC Journals Harlan Krumholz Justine VarieurTurco American College of Cardiology (4/10) From STEP-HFpEF, Mikhail Kosiborod and team offer new insights about semaglutide and inflammation, atrial fibrillation, and cardiac remodeling

More content coming out to support European Society of Cardiology #ESC2024 presentations for Day #3. Looking forward to #FINEARTSHF and discussions on emerging role of nonsteroidal #MRA for HFmrEF/HFpEF Stay tuned for more JACC Journals content to supplement discussion. Link is below.

🔥 fresh SoA review 🔥 JACC Journals To supplement discussion of #MRA European Society of Cardiology News European Society of Cardiology We comprehensively examine the current evidence regarding MRAs for HF and the future direction of nonsteroidal MRA research while exploring the causes of MRA underutilization.

HFSA announces late-breaking research for 2024 annual meeting Check out: HuMAIN, FINEARTS, STEP HFpEF And I’ll be presenting CARE-HK in HF ⁦Mikhail Kosiborod⁩ ⁦Steve Greene⁩ cardiovascularbusiness.com/topics/profess…